Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17–mediated inflammation
Lico B alleviates psoriasis by targeting SCD1 to modulate lipid metabolism, inhibit keratinocyte hyperproliferation, and dampen Th17/IL-17-driven inflammation. This multimodal mechanism positions Lico B as a novel therapeutic candidate for psoriasis and related inflammatory-metabolic dermatoses.
Authors
- M. Li
- 阿部 稔雄
- Manling Jiang (ORCID: https://orcid.org/0009-0009-3508-6389)
- Jiao Liu (ORCID: https://orcid.org/0000-0003-0304-241X)
- Guoping Li (ORCID: https://orcid.org/0000-0002-5277-2091)
- Junyi Wang (ORCID: https://orcid.org/0000-0002-3792-3920)
- Vws Wong
- Chenxu Yang
- Liang Jin (ORCID: https://orcid.org/0000-0002-1954-4345)
- Yao Liu
- Keyue Wang
- Xiaolan Li
- Xiang He
- Qin Ran (ORCID: https://orcid.org/0009-0008-5889-9211)
- Peng Song
- Lei Zhang
Institutions
- Macau University of Science and Technology (MO)
- Third People's Hospital of Chengdu (CN)
- Ministry of Education (TH)
- Southwest Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3389/fphar.2026.1754729
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province